GH
Guardant Health, Inc.
GH has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over GH overall, supported by stronger fundamentals.
GH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
GH's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
GH PE Valuation
GH has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
GH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect GH's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
GH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.69 | -$0.48 |
| Q2 2026 | -$3.50 | -$0.15 |
| Q1 2026 | -$3.40 | -$0.01 |
| Q4 2025 | -$3.32 | +$0.24 |
| Q3 2025 | -$3.21 | +$1.03 |
| Q2 2025 | -$3.35 | +$0.74 |
| Q1 2025 | -$3.39 | +$0.53 |
| Q4 2024 | -$3.56 | +$0.72 |
GH is still losing money, but less than at its worst: $3.69 per share over the past year, against $6.50 at its worst in early 2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over GH on earnings quality, reporting a profit while its opponent remains loss making.
GH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $361M | +36% |
| Q2 2026 | $335M | +44% |
| Q1 2026 | $301.7M | +48% |
| Q4 2025 | $281.3M | +39% |
| Q3 2025 | $265.2M | +39% |
| Q2 2025 | $232.1M | +31% |
| Q1 2025 | $203.5M | +21% |
| Q4 2024 | $201.8M | +30% |
GH's revenue has grown year over year every quarter since late 2020: $361M last quarter, up 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -37% | +0.5 points |
| Q2 2026 | -39% | +7.3 points |
| Q1 2026 | -40% | +14 points |
| Q4 2025 | -43% | +20 points |
| Q3 2025 | -37% | +24 points |
| Q2 2025 | -46% | +11 points |
| Q1 2025 | -55% | +4.6 points |
| Q4 2024 | -62% | +65 points |
GH's operating margin was −37% last quarter, up 0.5 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over GH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over GH on profitability, with a higher operating margin.
GH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.2M | +$8.6M |
| Q2 2026 | -$69.5M | -$3.6M |
| Q1 2026 | -$71.2M | -$4.1M |
| Q4 2025 | -$54.2M | +$29.2M |
| Q3 2025 | -$45.8M | +$9.5M |
| Q2 2025 | -$65.9M | +$33.1M |
| Q1 2025 | -$67.1M | -$29.9M |
| Q4 2024 | -$83.4M | -$583K |
GH has burned cash in almost every quarter: −$232M over the past year, against −$262M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over GH on cash generation, producing positive trailing cash flow while its opponent burns cash.
GH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.6M shares |
| 1 year | +7.7% | +9.6M shares |
| 3 years | +14% | +16.7M shares |
| 5 years | +33% | +33M shares |
| Available history | +48% | +43.8M shares |
GH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $45M |
| Q4 2019 | — |
GH hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
GH Net Leverage
GH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
GH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.5 | Neutral |
| Stochastic | 45.3 | Neutral |
GH's weekly RSI is 52 (neutral) and its Stochastic is 45 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
GH PE vs Healthcare Sector
GH has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
GH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $166.8 | 7.2% below |
| 20 week MA | $164.2 | 5.7% below |
| 50 week MA | $128.2 | 21% above |
| 100 week MA | $90.8 | 71% above |
| 200 week MA | $59.1 | 162% above |
GH has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 162% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over GH on trend strength, trading above more of its moving averages.
GH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.8 | $133.8 | +70% |
| 2021 | $133.8 | $97.5 | -27% |
| 2022 | $97.5 | $27.9 | -71% |
| 2023 | $27.9 | $27.1 | -3% |
| 2024 | $27.1 | $30.4 | +13% |
| 2025 | $30.4 | $103.0 | +238% |
| 2026 YTD | $103.0 | $154.9 | +50% |
GH's yearly returns have swung widely, from +238% in 2025 to −71% in 2022. It's up 50% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over GH on returns for 2026, with the stronger performance.